BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Breast Cancer
,
Stem cell
,
Anticancer prodrugs
,
Lipitor
,
rs2476601
,
PDX1
,
Apoptosis
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
complement c4b
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Bioengineered 3D Skeletal Muscle Model Reveals Complement 4b as a Cell-Autonomous Mechanism of Impai…
Multifaceted Activities of Seven Nanobodies against Complement C4b.
A case report of complement C4B deficiency in a patient with steroid and IVIG-refractory anti-NMDA r…
Human Complement C4B Allotypes and Deficiencies in Selected Cases With Autoimmune Diseases.
The Complement System in Retinal Detachment with Choroidal Detachment.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b F…
Complement and Cardiovascular Risk in Adolescents
Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@S…
Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b Adjuvanted …
Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic Brain Injury
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ